Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma

Medical Oncology

Volumn 22, Issue 1, 2005, Pages 39-44

  Tas, Faruk ^a   Duranyildiz, Derya ^a   Oguz, Hilal ^a   Disci, Rian ^a   Kurul, Sidika ^a   Yasasever, Vildan ^a   Topuz, Erkan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Matrix metalloproteinase; Melanoma; MMP 3; Serum; TIMP 1

Indexed keywords

STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MITOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SKIN CANCER; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR REGRESSION; ULCER;

EID: 18444404665     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/mo:22:1:039     Document Type: Article

References (23)

1. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. Natl Cancer Inst 1997;89:1260-1270.
2. Duffy MJ, McCarthy K. Matrix metalloproteinases in cancer: prognostic markers and targets for therapy. Int J Oncol 1998;12:1343-1348.
3. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res 2000;6:4823-4830.
4. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002;99:157-166.
5. Hofmann UB, Westphal JR, van Muijan GNP, Ruiter D. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000;115:337-344.
6. Kahari VM, Saarialho-Kere U. Matrix proteinases and their inhibitors in tumor growth and invasion. Ann Med 1999;31:34-45.
7. Gojhi K, et al. Elevation of serum levels of matrix metalloproteinase-2 and -3 as a new predictors of recurrence in patients with urothelial carcinoma. Cancer 1996;78:2379-2387.
8. Liokumovich P, et al. Expression of metalloproteinases endometrial stromal sarcoma: immunohistochemical study using image analysis. J Clin Pathol 1999;52:198-202.
9. Michael M, et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 1999;17:1802-1808.
10. El-Shabrawi Y, Ardjomand N, Radner H, Ardjomand N. MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma. J Pathol 2001;194:201-206.
11. Nemeth JA, Rafe A, Steiner M, Goolsby CL. TIMP-2 growth stimulatory activity: a concentration and cell type-specific response in the presence of insulin. Exp Cell Res 1996;224:110-115.
12. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-122.
13. Walker RA, Woolley DE. Immunolocalisation studies of matrix metalloproteinases-1, -2, and -3 in human melanoma. Virchows Arch 1999;435:574-579.
14. Hofmann UB, et al. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br J Cancer 1999;81:774-782.
15. Asai M, et al. Differential regulation of MMP-9 and TIMP-2 expression in malignant melanoma developed in metallothionein/RET transgenic mice. Jpn J Cancer Res 1999;90:86-92.
16. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Matrix metalloproteinase expression in malignant melanoma: tumorextracellular matrix interactions in invasion and metastasis. In Vivo 2001:15:57-64.
17. de Lorenzo MS, et al. Altered tumor angiogenesis and metastasis of B16 melanoma in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1. In Vivo 2003;17:45-50.
18. Hoashi T, Kadono T, Kikuchi E, Etoh T, Tamaki T. Differential growth regulation in human melanoma cell lines by TIMP-1 and TIMP-2. Biochem Biophys Res Commun 2001;288:371-379.
19. Airola K, et al. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999;80:733-743.
20. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 2002;97:432-438.
21. Saida T. Recent advances in melanoma. J Dermatol Sci 2001;26:1-13.
22. Meric JB, Beaudeux JL, Mouawad R, Cajfinger F, Khayat D, Rixe O. Relevance of matrix metalloproteinase (MMP) plasma levels in malignant melanoma (MMM). Proc Am Soc Clin Oncol 2003;22:721, abstract 2899.
23. Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Kim DK, Das Gupta TK. Beta 1 integrin expression in malignant melanoma predicts occult lymph node metastasis. Surgery 1995;118:669-673.